Saturday 17 October 2026
Export CTSO’s income statement to Excel — free account
Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.11
1.05
+34.31%
Follow CTSO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.63 | 0.95 | 1.07 | 1.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(40.29) | (30.56) | (8.24) | (22.74) | |
P/B ratio |
0.00 | 16.18 | 6.74 | 6.50 | |
Price to Tangible BV |
0.00 | 0.00 | 14.85 | 11.06 | |
EV/Sales |
0.98 | 1.28 | 1.42 | 1.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.97) | (4.73) | (4.26) | (6.89) | |
EV/FCF |
(3.85) | (4.54) | (4.12) | (6.72) | |
Quick Ratio |
0.47 | 0.73 | 1.42 | 1.48 | |
Current Ratio |
0.66 | 1.09 | 2.13 | 2.11 | |
Net Debt/EBITDA |
(6.48) | (5.11) | (2.78) | (3.10) | |
Debt/Assets |
45.42% | 41.81% | 37.72% | 31.84% | |
Debt/Equity |
(22.96) | 7.73 | 2.82 | 1.62 | |
Asset Turnover |
0.87 | 0.81 | 0.81 | 0.79 | |
Operating CF/Net income |
0.13 | 0.23 | 0.88 | 0.81 | |
Capex/Depreciation |
0.01 | (0.07) | (0.46) | 0.09 | |
Interest Coverage |
(3.04) | (3.55) | (5.88) | (4.44) | |
Research and Development Expense of Revenue |
15.08% | 11.56% | 13.45% | 9.68% | |
Selling, General and Administrative Expense of Revenue |
82.67% | 91.93% | 102.19% | 90.77% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.07 | 0.00 | |
Share Based Compensation of Revenue |
3.82% | 6.14% | 6.86% | 7.81% | |
Graham Net Nets |
(0.98) | (0.58) | (0.44) | (0.26) | |
Graham Number |
5.59 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(77.54%) | (33.57%) | (20.34%) | (19.27%) | |
Free Cash Flow Yield |
(40.11%) | (29.53%) | (32.17%) | (17.30%) | |
Revenue per Share |
3.07 | 2.83 | 2.97 | 3.02 | |
Operating CF per Share |
(0.19) | (0.37) | (1.55) | (0.82) | |
Capex per Share |
0.00 | (0.01) | (0.09) | 0.02 | |
Free Cash Flow per Share |
(0.18) | (0.39) | (1.64) | (0.80) | |
Cash per Share |
1.41 | 1.53 | 2.01 | 2.40 | |
Shareholders Equity per Share |
(0.24) | 0.70 | 1.90 | 2.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.24) | 0.70 | 1.90 | 2.87 | |
Free Cash Flow |
(0.58) | (1.21) | (5.12) | (2.52) | |
Working Capital |
(8.29) | 1.45 | 10.93 | 11.20 | |
Capital Expenditures |
0.01 | (0.05) | (0.29) | 0.06 | |
Net Current Asset Value |
(22.97) | (20.61) | (17.64) | (15.42) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.03 | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.26 | 7.41 | 7.44 | 7.03 | |
Average Payables |
2.70 | 3.23 | 3.10 | 2.69 | |
Average Inventory |
3.70 | 3.75 | 4.01 | 3.62 | |
Average Assets |
42.98 | 45.67 | 45.78 | 46.78 | |
Average Common Equity |
5.42 | 8.37 | 8.51 | 11.01 |
Columns are period end dates